Ramipril angiotensin-Converting Enzyme Inhibitors

Zabien - Tritace - Acovil - Carasel - Vesdil - Ramace - Delix - Altace - Triatec      

pdf
pathology Demonstrated benefit and harm k      
acute myocardial infarction

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
diabetes type 2

versus placebo or control

No demonstrated result for efficacy

ramipril inferior to placebo in terms of normoglycemia in DREAM ramipril, 2006

3 trialsmeta-analysis
diabetic kidney disease

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
heart failure

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
heart failure

versus placebo or no treatment

No demonstrated result for efficacy

7 trialsmeta-analysis
hypertension

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
hypertension

versus ACEIs

No demonstrated result for efficacy

1 trialmeta-analysis
hypertension

versus beta-blockers

No demonstrated result for efficacy

1 trialmeta-analysis
hypertension

versus calcium-channel blockers

No demonstrated result for efficacy

1 trialmeta-analysis
impaired fasting glucose

versus placebo or control

No demonstrated result for efficacy

ramipril inferior to placebo in terms of normoglycemia in DREAM ramipril, 2006

1 trialmeta-analysis
miscellaneous

versus

No demonstrated result for efficacy

telmisartan + ramipril inferior to ramipril in terms of Insuffisance rénale in ONTARGET (association vs ramipril), 2008

telmisartan + ramipril inferior to ramipril in terms of hypotension in ONTARGET (association vs ramipril), 2008

telmisartan + ramipril inferior to ramipril in terms of Arrêt pour effet secondaire in ONTARGET (association vs ramipril), 2008

telmisartan + ramipril inferior to telmisartan in terms of Insuffisance rénale in ONTARGET (association vs telmisartan), 2008

telmisartan + ramipril inferior to telmisartan in terms of Toux in ONTARGET (association vs telmisartan), 2008

telmisartan + ramipril inferior to telmisartan in terms of hypotension in ONTARGET (association vs telmisartan), 2008

telmisartan + ramipril inferior to telmisartan in terms of Arrêt pour effet secondaire in ONTARGET (association vs telmisartan), 2008

2 trialsmeta-analysis
patients at high risk for cardiovascular events

versus placebo or control

No demonstrated result for efficacy

ramipril inferior to placebo in terms of Toux in HOPE, 2000

ramipril inferior to placebo in terms of Angiodème in HOPE, 2000

1 trialmeta-analysis
patients at high risk for cardiovascular events

versus

No demonstrated result for efficacy

telmisartan + ramipril inferior to ramipril in terms of Insuffisance rénale in ONTARGET (association vs ramipril), 2008

telmisartan + ramipril inferior to ramipril in terms of hypotension in ONTARGET (association vs ramipril), 2008

telmisartan + ramipril inferior to ramipril in terms of Arrêt pour effet secondaire in ONTARGET (association vs ramipril), 2008

telmisartan + ramipril inferior to telmisartan in terms of Insuffisance rénale in ONTARGET (association vs telmisartan), 2008

telmisartan + ramipril inferior to telmisartan in terms of Toux in ONTARGET (association vs telmisartan), 2008

telmisartan + ramipril inferior to telmisartan in terms of hypotension in ONTARGET (association vs telmisartan), 2008

telmisartan + ramipril inferior to telmisartan in terms of Arrêt pour effet secondaire in ONTARGET (association vs telmisartan), 2008

2 trialsmeta-analysis